Cerebrovascular disease and stroke

Pappachan, John; Kirkham, Fenella J.

doi:10.1136/adc.2008.142836

Cited by 59 publications

(37 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…74 All guidelines agree on not recommending fibrinolytic therapy with tPA or alteplase for childhood arterial ischemic stroke, except for cases occurring within 3 hours after stroke. 79 As prevention of stroke, AHA 77 and ACCP 76 recommend anticoagulation therapy only for selected prothrombotic states, although IBD is not specifically cited; UK-RCP 74 advises referral to a hematologist. Thrombophilic screening and alternatives to oral contraception are recommended only after a first TE event, 77 and they are not specifically discussed for IBD patients.…”

Section: Discussionmentioning

confidence: 99%

Thromboembolism in pediatric inflammatory bowel disease: Systematic review

Lazzerini¹,

Bramuzzo²,

Maschio³

et al. 2011

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Thromboembolism in pediatric inflammatory bowel disease: Systematic review

Lazzerini¹,

Bramuzzo²,

Maschio³

et al. 2011

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

show abstract

“…ACVD accounts for 10% of mortality among all diseases and is one of the three major causes of mortality in humans (18). Additionally, ACVD events result in high rates of disability due to lasting neurological damage (2).…”

Section: Discussionmentioning

confidence: 99%

Correlation between ischemia-modified albumin and lipid levels in patients with acute cerebrovascular disease

et al. 2012

View full text Add to dashboard Cite

Abstract. Acute cerebrovascular disease (ACVD) is associated with high morbidity and mortality rates, however, molecular markers to aid in its early detection are lacking. In this study, we examined the correlation between serum ischemia-modified albumin (IMA), a marker used to identify ischemic events in the heart, and blood lipids in patients with ACVD. Serum IMA levels were determined by enzyme-linked immuno sorbent assay, and total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein cholesterol (HDL) and triglyceride (TG) levels were determined biochemically in 62 patients with cerebral infarction (CI), 40 patients with intracerebral hemorrhage (ICH), 18 patients with subarachnoid hemorrhage (SAH) and 100 healthy individuals (controls). Serum IMA levels were significantly higher in each of the ACVD groups compared to the control group (CI, 80.81±11.97 U/ml; ICH, 80.25±10.91 U/ml; SAH, 74.43±11.39 U/ml and control, 41.08±5.10 U/ml; P<0.05). Additionally, serum TC, LDL and TG levels significantly increased, while serum HDL significantly decreased in the ACVD groups compared to the control group (P<0.05). A positive correlation was found between serum IMA levels and serum TC, LDL and TG levels in the ACVD patients, while serum IMA levels were negatively correlated with serum HDL levels (P<0.05). Thus, serum IMA increased following an ACVD event and was closely correlated with changes in the blood lipid levels. These factors, when combined, may allow the development of molecular markers for an earlier diagnosis of ACVD.

show abstract

“…Studies have shown that CVD is typically associated with ischemic stroke [4] . Ischemic stroke featuring functional disturbance and morphological damage of brain is caused by CVD, which affects the brain blood supply and leads to a cascade of metabolic alterations.…”

Section: Introductionmentioning

confidence: 99%

Small-animal PET demonstrates brain metabolic change after using bevacizumab in a rat model of cerebral ischemic injury

Dong

Song

et al. 2014

Neurosci. Bull.

View full text Add to dashboard Cite

To evaluate the effect of bevacizumab on cerebral ischemia, we used 2-deoxy-2-18 F-fluoro-D-glucose ( 18 F-FDG) small-animal positron emission tomography (PET) in the middle cerebral artery occlusion (MCAO) rat model. After baseline neurologic function tests and PET studies, MCAO Sprague-Dawley rats received bevacizumab or normal saline (controls). Weekly PET imaging and neurologic function tests showed that the 18 F-FDG accumulation in the bevacizumab group was similar to that in the controls during the fi rst 2 weeks, but lower than in controls at weeks 3 and 4. However, no difference was found in neurological scores between the groups. The number of von Willebrand factor-positive cells in the bevacizumab group was lower than that in controls. The expression of vascular endothelial growth factor was higher than in controls at week 4. These results suggested that bevacizumab does not infl uence functional recovery in this model of cerebral ischemia during a 4-week period, but inhibits vascular formation and metabolic recovery, which may be considered in cancer patients with a recent ischemic stroke.

show abstract

Cerebrovascular disease and stroke

Cited by 59 publications

References 51 publications

Thromboembolism in pediatric inflammatory bowel disease: Systematic review

Thromboembolism in pediatric inflammatory bowel disease: Systematic review

Correlation between ischemia-modified albumin and lipid levels in patients with acute cerebrovascular disease

Small-animal PET demonstrates brain metabolic change after using bevacizumab in a rat model of cerebral ischemic injury

Contact Info

Product

Resources

About